The National Institutes of Health is now hoping to launch its first big clinical trials of potential treatments for patients experiencing long-term symptoms from COVID-19 as early as October, according to a top federal official overseeing the plans.
In a paper published in June in the Journal of the American Chemical Society, the research team described how they developed a way to attach SARS-CoV-2 antibodies to sugar and then have the glucose reader measure those sugar levels, which reflect the antibody levels.
The majority of people likely infected with the omicron variant that causes COVID-19 were not aware they contracted the virus, which likely played a role in the rapid spread of omicron, according to a study published this week.
